A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

Prof Wee Loon Ong
24 September, 2025

Prostate Cancer Month: Focus on the TROG Genitourinary Working Party

To mark Prostate Cancer Month in September, we asked

24 September, 2025

TROG members and staff celebrate World Radiotherapy Awareness Day

LATEST NEWS: 24 September 2025 TROG Cancer Research staff